Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.57 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772274 | 0.95 | MAPK14 (0.60) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6775176 | 0.92 | MAPK14 (0.66) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6774295 | 0.92 | MAPK14 (0.55) | MAPK14BRD4BRDT | |
| SCHEMBL6768633 | 0.91 | MAPK14 (0.56) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6769842 | 0.91 | MAPK14 (0.56) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6773931 | 0.91 | MAPK14 (0.54) | MAPK14BRD4BRDT | |
| SCHEMBL6772997 | 0.91 | MAPK14 (0.55) | MAPK14BRD4SCN9A | |
| SCHEMBL6774535 | 0.91 | MAPT (0.57) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6773952 | 0.91 | MAPK14 (0.56) | MAPK14BRD4MAPTL3MBTL1BRDT | |
| SCHEMBL6768581 | 0.90 | MAPK14 (0.44) | MAPK14BRD4MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-01-16 | — | — | US | claimed |
| US-6727364-B2 | ANTIINFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY | 2004-04-27 | — | — | US | disclosed |
| EP-1383759-A1 | TRIAZOLE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY | The Procter & Gamble Company (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | PROCTER & GAMBLE COMPANY, THE | 2003-01-16 | — | — | US | disclosed |
| WO-2002088108-A1 | TRIAZOLE COMPOUNDS USEFUL IN TREATING DISEASES ASSOCIATED WITH UNWANTED CYTOKINE ACTIVITY | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013712-A1 | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | IL4, IL1A, IL2 | MAPK14 3429/4885BRD4 389/4885SCN9A 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.